4-(Chloromethyl)-N,N,5-trimethyl-1H-imidazole-1-sulphonamide | 122852-93-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(Chloromethyl)-N,N,5-trimethyl-1H-imidazole-1-sulphonamide
• 英文别名: 4-(chloromethyl)-N,N,5-trimethylimidazole-1-sulfonamide
• CAS: 122852-93-1
• 化学式: C₇H₁₂ClN₃O₂S
• 分子量: 237.71
• InChiKey: DGJKKXAFDOWIQI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  63.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-[(1-Methyl-1H-indol-2-yl)ethyl]trifluoroacetamide 、 4-(Chloromethyl)-N,N,5-trimethyl-1H-imidazole-1-sulphonamide 生成 N-((1-(N,N-dimethylsulfamoyl)-5-methyl-1H-imidazol-4-yl)methyl)-2,2,2-trifluoro-N-(2-(1-methyl-1H-indol-2-yl)ethyl)acetamide
  参考文献：
  名称：

  COATES, IAN HAROLD;NORTH, PETER CHARLES;OXLORD, ALEHANDER WILLIAM

  摘要：

  DOI：
• 作为产物：
  描述：

  4-(hydroxymethyl)-N,N,5-trimethyl-1H-imidazole-1-sulphonamide 在 甲基磺酰氯 、 三乙胺 、 lithium chloride 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 4-(Chloromethyl)-N,N,5-trimethyl-1H-imidazole-1-sulphonamide
  参考文献：
  名称：

  [EN] ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES
  [FR] PYRIDOPYRAZINES ANTI-CANCÉREUSES PAR L'INHIBITION DE KINASES DE FGFR

  摘要：

  这项发明涉及新的吡啶吡嗪衍生物化合物，包括含有该化合物的药物组合物，制备该化合物的方法以及利用该化合物治疗疾病，例如癌症。

  公开号：

  WO2013061080A1

文献信息

• Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
  申请人：Glaxo Group Limited

  公开号：US05360800A1

  公开（公告）日：1994-11-01

  The invention relates to tricyclic lactams of the general formula (I) ##STR1## wherein Im represents an imidazolyl group of the formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenyl C.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl or phenoxymethyl, one of the groups represented by R.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenyl C.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkhyl group; n represents 2 or 3; and physiologically acceptable salts and solvates thereof. The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT.sub.3 receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.

  本发明涉及一般式（I）的三环内酰胺，其中Im代表公式的咪唑基：##STR2## R.sup.1代表氢原子或从C.sub.1-6烷基，C.sub.3-6烯基，C.sub.3-10炔基，C.sub.3-7环烷基，C.sub.3-7环烷基C.sub.1-4烷基，苯基，苯基C.sub.1-3烷基，苯基甲氧甲基，苯氧乙基或苯氧甲基中选择的基团之一，由R.sup.2，R.sup.3和R.sup.4表示的三个基团中的一个是氢原子或C.sub.1-6烷基，C.sub.3-7环烷基，C.sub.3-6烯基，苯基或苯基C.sub.1-3烷基，其余两个基团可以相同也可以不同，分别表示氢原子或C.sub.1-6烷基；n代表2或3；以及其生理上可接受的盐和溶剂合物。这些化合物是5-HT.sub.3受体的有效和选择性拮抗剂，例如，它们在治疗精神疾病，焦虑症和恶心和呕吐症方面是有用的。
• Lactam derivatives
  申请人：GLAXO GROUP LIMITED

  公开号：EP0306323A2

  公开（公告）日：1989-03-08

  The invention relates to tricyclic lactams of the general formula (I) wherein Im represents an imidazolyl group of the formula: and R¹ represents a hydrogen atom or a group selected from C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₁₀alkynyl, C₃₋₇cycloalkyl, C₃₋₇cycloalkylC₁₋₄alkyl, phenyl, phenylC₁₋₃alkyl, phenylmethoxymethyl, phenoxyethyl, phenoxymethyl, -CO₂R⁵, -COR⁵, -CONR⁵R⁶ or -SO₂R⁵ (wherein R⁵ and R⁶, which may be the same or different, each represent a hydrogen atom, a C₁₋₆alkyl or C₃₋₇cycloalkyl group or a phenyl or phenylC₁₋₄alkyl group, in which the phenyl group is optionally substituted by one or more C₁₋₄alkyl, C₁₋₄alkoxy or hydroxy groups or halogen atoms, with the proviso that R⁵ does not represent a hydrogen atom when R¹ represents a group -CO₂R⁵ or -SO₂R⁵); one of the groups represented by R², R³ and R⁴ is a hydrogen atom or a C₁₋₆alkyl, C₃₋₇cycloalkyl, C₃₋₆alkenyl, phenyl or phenylC₁₋₃alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C₁₋₆alkyl group; n represents 2 or 3; and physiologically acceptable salts and solvates thereof. The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT₃ receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.

  本发明涉及通式 (I) 的三环内酰胺 其中 Im 代表式中的咪唑基团： 和 R¹ 代表氢原子或选自 C₁₋₆烷基、C₃₋₆烯基、C₃₋₁₀炔基、C₃₋₇ 环烷基、C₃₋₇ 环烷基、C₁₋₄烷基、苯基、C₁₋₃烷基、苯甲氧基甲基、苯氧基乙基、苯氧基甲基、-CO₂R⁵、-COR⁵、-CONR⁵R⁶或-SO₂R⁵（其中 R⁵ 和 R⁶可以相同或不同、各自代表氢原子、C₁₋₆烷基或 C₃₋₇环烷基或苯基或苯基 C₁₋₄ 烷基，其中苯基任选被一个或多个 C₁₋₄ 烷基取代、C₁₋₄烷氧基或羟基或卤素原子取代，但当 R¹ 代表-CO₂R⁵或-SO₂R⁵基团时，R⁵不代表氢原子；） R²、R³和R⁴所代表的基团之一是氢原子或C₁₋₆烷基、C₃₋₇环烷基、C₃₋₆烯基、苯基或苯基 C₁₋₃烷基，而另外两个基团（可以相同或不同）分别代表氢原子或 C₁₋₆烷基； n 代表 2 或 3； 及其生理上可接受的盐和溶剂。 这些化合物是 5-HT₃ 受体上 5-HT 效应的强效选择性拮抗剂，可用于治疗精神障碍、焦虑、恶心和呕吐等疾病。
• ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES
  申请人：Astex Therapeutics Limited

  公开号：EP2776435B1

  公开（公告）日：2018-06-27
• SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS
  申请人：ASTEX THERAPEUTICS LIMITED

  公开号：US20160235744A1

  公开（公告）日：2016-08-18

  The invention relates to new pyridopyrazine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
• US5183820A
  申请人：——

  公开号：US5183820A

  公开（公告）日：1993-02-02